論文（英文）

Hirano D, Fujinaga S, Shinozaki T, Endo A, Watanabe T, Murakami H, Ida H. Optimal urinary protein-to-creatinine ratio as a renal biopsy criterion in children with asymptomatic proteinuria. Clin Nephrol. 2014;82(2):115-21.
Shinozaki T, Matsuyama Y, Ohashi Y. Estimation of controlled direct effects in time-varying treatments using structural nested mean models: application to a primary prevention trial for coronary events with pravastatin. Stat Med. 2014;33(18):3214-28.
Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S.　Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes.　Journal of Diabetes and its Complications 2014; 28(2): 185-190
Aramaki O, Takayama T, Higaki T, Nakayama H, Ohkubo T, Midorikawa Y, Moriguchi M, Matsuyama Y. Decreased blood loss reduces postoperative complications in resection for hepatocellular carcinoma. Journal of Hepato-biliary Pancreatic Sciences 2014; 21(8): 585-591.
Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Annals of Surgical Oncology 2014; 21(6): 1817-1824.
Naito S, Imamura H, Tukada A, Matsuyama Y, Yoshimoto J, Sugo H, Ishizaki Y, Kawasaki S. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver International 2014; 34(5): 802-813.
Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M; for the Liver Cancer Study Group of Japan. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: An analysis of 1160 cases from a nationwide survey. Annals of Surgery 2014; 259(3): 532-542.
Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Annals of Surgery 2014; 259(2): 336-345.
Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: Report of a Japanese nationwide survey. Annals of Surgery 2014; 259(1): 166-170.
Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014;15:886-93
Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, Otomo K, Horita T, Oba K, Kondo M, Mukai M, Yanai M, Fukasawa Y, Atsumi T. Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014; 23:1124-32.
Fujimoto S, Kondo T, Yamamoto H, Yokoyama N, Tarutani Y, Takamura K, Urabe Y, Konno K, Nishizaki Y, Shinozaki T, Kihara Y, Daida H, Isshiki T, Takase S. Development of new risk score for pre-test probability of obstructive coronary artery disease based on coronary CT angiography. Heart Vessels. 2015;30(5):563-71.
Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T, Amengual O, Horita T, Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford). 2014 Apr 24.
Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Yokota I, Ohashi Y, Eguchi K. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer - CSP-HOR 13. J Thorac Oncol. 2014; 9:231-8.
Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H. Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol. 2014;113(3):441-5.
Nakai Y, Inoue T, Toda H, Toyomaki A, Nakato Y, Nakagawa S, Kitaichi Y, Kameyama R, Hayashishita Y, Wakatsuki Y, Oba K, Tanabe H, Kusumi I. The influence of childhood abuse, adult stressful life events and temperaments on depressive symptoms in the nonclinical general adult population. J Affect Disord 2014; 158: 101-7.
Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, Takahashi K, Oka M, Nakamura D, Tsunedomi R, Okayama N, Mishima H, Kobayashi M. Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations. Mol Diagn Ther 2014; 18: 333-42.
Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C, Bando H, Sakamoto J, Oba K, Mishima H. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 2014; 34: 1967-73.
Cho H, Yoshikawa T, Oba MS, Hirabayashi N, Shirai J, Aoyama T, Hayashi T, Yamada T, Oba K, Morita S, Sakamoto J, Tsuburaya A. Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: The adjuvant exercise for general elective surgery (AEGES) study group. Ann Surg Oncol 2014; 21: 2044-50.
Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H. Relative increase in lymphocytes from as early as one month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 2014; 99: 41-52.

TOP